InflaRx N.V. has regained compliance with the Nasdaq Stock Market's minimum bid price requirement [1, 2].
Maintaining a minimum share price is critical for public companies to avoid delisting from major exchanges. This milestone ensures the biopharmaceutical firm continues its trading status on the Nasdaq, providing the company with continued access to public capital markets.
The company said the update on April 28, 2024 [1]. This announcement followed a formal notice received from Nasdaq on April 27, 2024 [1].
To satisfy the exchange's rules, InflaRx shares had to close at or above $1.00 for 10 consecutive business days [2]. The company met this requirement during a period between April 13 and April 24, 2024 [2].
Nasdaq requires listed companies to maintain a minimum bid price to ensure liquidity and stability for investors. When a stock falls below this threshold, the exchange issues a deficiency notice giving the firm a specific window to rectify the price drop, typically through organic price growth or a reverse stock split.
InflaRx achieved this recovery through market performance, as its shares remained at or above the $1.00 mark for the necessary duration [2]. The company said it did not use corporate actions, such as a stock split, to reach this specific compliance goal [1, 2].
“InflaRx N.V. has regained compliance with the Nasdaq Stock Market's minimum bid price requirement”
Regaining compliance removes the immediate threat of delisting, which often triggers institutional sell-offs and limits a company's ability to raise funds. For a biopharmaceutical company, maintaining a listing on a major U.S. exchange is essential for visibility and credibility with global investors during the capital-intensive process of drug development.
